What happened
Cencora, the US pharmaceutical distribution and services group, has signed a definitive agreement to acquire American Oncology Network, a Fort Myers, Florida based physician-led network of more than 350 oncology providers practicing across 21 states. The deal was announced on 21 October 2026 and values AON at an enterprise value of $2.4 billion. That consists of $2.3 billion at closing plus contingent value rights worth up to $100 million, payable if certain conditions are met.
Cencora already holds about 4 percent of AON. Some AON stockholders may roll over equity representing up to 25 percent of the business. If they retain that full stake, Cencora expects to pay roughly $1.7 billion in cash at closing to lift its ownership to 75 percent. The AON board approved the agreement on the unanimous recommendation of a special committee of independent directors. Completion still needs regulatory clearances and AON stockholder approval, and no closing date has been set. Cencora expects the deal to add to adjusted diluted earnings per share in the second year after closing, and says clinical decisions will stay with AON physicians.
Why it matters
This is a distributor buying its way deeper into the point of care. Community oncology is one of the most valuable channels in US specialty pharmaceuticals. Infused and injectable cancer drugs are high cost, they move through physician offices and clinics rather than retail pharmacies, and the practices that administer them depend on reliable distribution, purchasing support and revenue cycle help. Owning the management services organization, or MSO, that sits behind those practices gives a distributor more than a customer relationship. It gives it a durable role in how practices buy, operate and grow.
Cencora is not new to this model. In 2025 it agreed to take a majority stake in OneOncology, another physician-led network in which it had been a minority investor. AON now adds a second platform and, by the company’s own account, extends its oncology MSO presence into twelve more states. Read together, the two moves show a clear strategy: build the largest independent oncology support platform in the country, while keeping a physician-led label that matters to doctors weighing a sale.
The structure also says something. The rollover option keeps founding physicians and existing holders financially tied to the outcome, and the contingent value rights push part of the price into the future. That is a sensible way to pay for a growth asset while limiting the cost of getting the integration wrong.
Who feels it
Independent oncology practices. Practices still outside any network face a sharper choice. Joining a large, well-funded MSO brings capital, technology and purchasing scale, but it also means giving up some autonomy. Expect more outreach from networks backed by distributors, health systems and private equity.
Rival distributors and MSOs. McKesson, Cardinal Health and sponsor-backed oncology platforms compete for the same practices and the same specialty drug volumes. A second large network under Cencora raises the bar on what an MSO must offer to win and keep physicians.
Drug manufacturers. Oncology makers will deal with more concentrated buyers in community settings, with more influence over formulary choices, biosimilar uptake and site-of-care economics. Companies tracked in our healthcare and medical devices research will want to watch how this shifts channel strategy.
Payers and policymakers. Vertical ties between drug wholesalers and the practices that prescribe and administer drugs draw steady scrutiny. Payers will look for whether the combined platform lowers total cost of care or simply captures more margin along the chain.
What to watch
First, the regulatory path. A distributor owning physician practice managers is a vertical arrangement, and US antitrust agencies have shown more interest in healthcare roll-ups in recent years. The full terms, rollover mechanics and closing conditions are set out in Cencora’s announcement of the American Oncology Network agreement, and the stockholder vote and any agency review will set the real timeline.
Second, how the two networks fit together. OneOncology and AON have different practice profiles, and Cencora will need to decide whether to run them side by side or merge services such as group purchasing, data platforms and value-based care contracting. Overlap creates savings, but forcing a single model on physicians risks the attrition that hurts physician-led businesses most.
Third, physician retention and recruitment. The value of an MSO rests on keeping doctors and adding new practices. Watch for departures after closing, and for how quickly the network grows in the twelve new states.
Fourth, management commentary on the next Cencora earnings call, where investors will look for detail on funding, integration costs and the path to the promised earnings lift. The main risks are regulatory delay, reimbursement pressure on physician-administered drugs, and the cultural strain of folding a fast-growing independent network into a large corporate owner. The broader signal is plain: in US specialty care, distribution scale is no longer enough, and the big wholesalers are paying to sit closer to the prescriber.